Halda Therapeutics
Halda Therapeutics is a biotechnology company developing RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, a novel class of cancer therapies designed to overcome drug resistance. Their lead program targets prostate and breast cancer, with a Phase 1 clinical trial expected to begin in the first half of 2025. The RIPTAC modality employs a "hold and kill" mechanism targeting specific proteins within cancer cells.
Buy Funded Startups lists
Funding Round: Series B+
Funding Amount: $126M
Date: 12-Aug-2024
Investors: Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital, Taiho Ventures, Canaan Partners, Access Biotechnology, Elm Street Ventures, Connecticut Innovations
Markets: Biotechnology, Oncology, Cancer Therapeutics
HQ: New Haven, Connecticut, United States
Founded: 2018
Website: https://haldatherapeutics.com/
LinkedIn: https://www.linkedin.com/company/halda-therapeutics/
Twitter: https://twitter.com/HaldaThera
Crunchbase: https://www.crunchbase.com/organization/halda-therapeutics
Leave a Comment
Comments
No comments yet.